Cargando…

Treatable Mechanisms in Asthma

Asthma is a heterogeneous condition, but firm identification of heterogeneity-focused treatments is still lacking. Dividing patients into subgroups of asthma pheno-/endotypes based on combined clinical and cellular biological characteristics and linking them to targeted treatments could be a potenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Cazzola, Mario, Ora, Josuel, Cavalli, Francesco, Rogliani, Paola, Matera, Maria Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956930/
https://www.ncbi.nlm.nih.gov/pubmed/33570719
http://dx.doi.org/10.1007/s40291-021-00514-w
_version_ 1783664545133232128
author Cazzola, Mario
Ora, Josuel
Cavalli, Francesco
Rogliani, Paola
Matera, Maria Gabriella
author_facet Cazzola, Mario
Ora, Josuel
Cavalli, Francesco
Rogliani, Paola
Matera, Maria Gabriella
author_sort Cazzola, Mario
collection PubMed
description Asthma is a heterogeneous condition, but firm identification of heterogeneity-focused treatments is still lacking. Dividing patients into subgroups of asthma pheno-/endotypes based on combined clinical and cellular biological characteristics and linking them to targeted treatments could be a potentially useful approach to personalize therapy for better outcomes. Nonetheless, there are still many problems related to the identification and validation of asthma phenotypes and endotypes. Alternatively, a precision-medicine strategy for the management of patients with airways disease that is free from the traditional diagnostic labels and based on identifying "treatable traits" in each patient might be preferable. However, it would represent a quite unsophisticated approach because the definition of a treatable trait is too imprecise. In fact, there is still no understanding of the mechanisms underlying treatable traits that allow directing any targeted therapies against any particular treatable trait. Fortunately, in-depth identification of underlying molecular pathways to guide targeted treatment in individual patients is in progress thanks to the improvement in big data management obtained from ‘-omic’ sciences that is greatly increasing knowledge concerning asthma.
format Online
Article
Text
id pubmed-7956930
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-79569302021-03-28 Treatable Mechanisms in Asthma Cazzola, Mario Ora, Josuel Cavalli, Francesco Rogliani, Paola Matera, Maria Gabriella Mol Diagn Ther Current Opinion Asthma is a heterogeneous condition, but firm identification of heterogeneity-focused treatments is still lacking. Dividing patients into subgroups of asthma pheno-/endotypes based on combined clinical and cellular biological characteristics and linking them to targeted treatments could be a potentially useful approach to personalize therapy for better outcomes. Nonetheless, there are still many problems related to the identification and validation of asthma phenotypes and endotypes. Alternatively, a precision-medicine strategy for the management of patients with airways disease that is free from the traditional diagnostic labels and based on identifying "treatable traits" in each patient might be preferable. However, it would represent a quite unsophisticated approach because the definition of a treatable trait is too imprecise. In fact, there is still no understanding of the mechanisms underlying treatable traits that allow directing any targeted therapies against any particular treatable trait. Fortunately, in-depth identification of underlying molecular pathways to guide targeted treatment in individual patients is in progress thanks to the improvement in big data management obtained from ‘-omic’ sciences that is greatly increasing knowledge concerning asthma. Springer International Publishing 2021-02-11 2021 /pmc/articles/PMC7956930/ /pubmed/33570719 http://dx.doi.org/10.1007/s40291-021-00514-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Current Opinion
Cazzola, Mario
Ora, Josuel
Cavalli, Francesco
Rogliani, Paola
Matera, Maria Gabriella
Treatable Mechanisms in Asthma
title Treatable Mechanisms in Asthma
title_full Treatable Mechanisms in Asthma
title_fullStr Treatable Mechanisms in Asthma
title_full_unstemmed Treatable Mechanisms in Asthma
title_short Treatable Mechanisms in Asthma
title_sort treatable mechanisms in asthma
topic Current Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956930/
https://www.ncbi.nlm.nih.gov/pubmed/33570719
http://dx.doi.org/10.1007/s40291-021-00514-w
work_keys_str_mv AT cazzolamario treatablemechanismsinasthma
AT orajosuel treatablemechanismsinasthma
AT cavallifrancesco treatablemechanismsinasthma
AT roglianipaola treatablemechanismsinasthma
AT materamariagabriella treatablemechanismsinasthma